Market Research Report
Antibiotics And The Quest For New Super Drugs:Technologies, Markets, Competitors And Opportunities-2017-2022 Analysis And Forecasts
|Published by||Amadee & Company, Inc.||Product code||301230|
|Published||Content info||299 pages
Delivery time: 1-2 business days
|Antibiotics And The Quest For New Super Drugs:Technologies, Markets, Competitors And Opportunities-2017-2022 Analysis And Forecasts|
|Published: July 11, 2017||Content info: 299 pages||
Antibiotics are drugs used to treat infections that are caused by bacteria.
The introduction of antibiotics is recognized as one of the most transformative events in medicine.
Prior to the introduction of the first antibiotics in the 1930s and 1940s, bacterial infections were often fatal, and invasive surgery was accompanied by a high risk of infectious complications.
Today, antibiotics are used routinely to treat and prevent infection.
However, drug- and multi-drug-resistant bacterial strains pose a serious threat in the clinical setting as they directly contribute to an increase in morbidity and mortality, as compared to the underlying disease itself.
Due to antibiotic resistance, new antibiotic super drugs are desperately needed to fight infections like MRSA, CRE, ESBLs and C. difficile.
And that is beyond dealing with diseases like drug-resistant Gonorrhea, which affects an estimated 78 million people globally, or TB, which affects 10 million people worldwide, or even the 1 million+ people in the U.S. who get hospitalized with Pneumonia annually.
Or bioweapons like Anthrax.
Unfortunately, it is hard to discover new antibiotics.
Further compounding the problem, from approximately 20 traditional pharmaceutical companies investing in antibiotic research in the 1980s, there are now only five with significant active internal research programs.
As a result, most novel antibiotic development is now being conducted by small biotech companies.
Over the last few years there has been a growing realization among the various stakeholders (Industry players, governments, authorities and medical charities) that something needs to be done to address the issues impacting antibiotic R&D, and avoid the looming socio-economic burden of antimicrobial resistance.
Current antibiotics work now, for the most part.
But if an epidemic of one of the multi-drug-resistant strains rapidly spreading across the globe happens, it will be too late to start funding the discovery of new antibiotics.
The need to invest is now, so there are options when the inevitable next black death appears.
This report addresses these issues.
Specifically, it provides:
In addition to 37 company profiles, the report contains 14 tables and 62 figures.